Seres Therapeutics (NASDAQ:MCRB – Free Report) had its price objective trimmed by The Goldman Sachs Group from $1.00 to $0.75 in a report released on Friday,Benzinga reports. The brokerage currently ...

Q4 2024 Earnings Call Transcript March 13, 2025 Seres Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.1, ...

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call ...

Seres Therapeutics Inc (MCRB) reports reduced net loss and strategic advancements in SER-155, while addressing ongoing ...

Piper Sandler analyst Edward Tenthoff maintained a Hold rating on Seres Therapeutics (MCRB – Research Report) today and set a price target of ...

Seres Therapeutics (NASDAQ:MCRB – Get Free Report) is projected to release its earnings data before the market opens on ...

Ping An P&C can customise compensation plans for losses incurred due to power battery failure in FAW Hongqi’s Hongqi Tiangong ...

Submit to FDA a draft protocol for the next study of SER-155 in allo-HSCT in Q2 2025.; Present SER-155 Phase 1b clinical and exploratory ...

Founder of China's Seres Auto Zhang Xinghai, a delegate to China's top political advisory body, said that competition in China's electric vehicle market is extremely intense on price and technology, ...

In a city like Chicago, where style meets sustainability, and high-end meets down-to-earth, Seres provides the right answer to footwear.

More Chinese electric vehicle companies — including Leapmotor, Li Auto and Seres Group — are starting to turn a profit after burning cash for years in their intense competition for the world ...

The Seres 5 is a compact electric crossover from China, now available in Europe. With 577 hp, the top-spec model sprints from 0 to 62 mph in just 4.2 seconds. It offers a competitive 482 km (300 ...